Federated Hermes Inc. purchased a new stake in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 135,061 shares of the company's stock, valued at approximately $288,000. Federated Hermes Inc. owned 0.18% of Perspective Therapeutics as of its most recent SEC filing.
Several other large investors have also made changes to their positions in CATX. Millennium Management LLC bought a new stake in shares of Perspective Therapeutics in the fourth quarter worth about $4,132,000. Two Sigma Advisers LP acquired a new stake in Perspective Therapeutics in the 4th quarter valued at approximately $484,000. JPMorgan Chase & Co. raised its position in Perspective Therapeutics by 498.3% in the 4th quarter. JPMorgan Chase & Co. now owns 149,045 shares of the company's stock valued at $475,000 after buying an additional 124,133 shares during the last quarter. Two Sigma Investments LP acquired a new stake in Perspective Therapeutics in the 4th quarter valued at approximately $2,075,000. Finally, Jump Financial LLC acquired a new stake in Perspective Therapeutics in the 4th quarter valued at approximately $688,000. Institutional investors and hedge funds own 54.66% of the company's stock.
Perspective Therapeutics Trading Up 3.5%
CATX stock traded up $0.14 during midday trading on Thursday, reaching $3.95. 382,834 shares of the company were exchanged, compared to its average volume of 949,464. The business has a 50-day moving average price of $3.74 and a two-hundred day moving average price of $2.97. Perspective Therapeutics, Inc. has a one year low of $1.60 and a one year high of $16.55.
Wall Street Analyst Weigh In
CATX has been the topic of a number of recent research reports. Royal Bank Of Canada raised Perspective Therapeutics from an "outperform" rating to a "moderate buy" rating and lifted their target price for the company from $15.00 to $16.00 in a research report on Tuesday, June 3rd. Truist Financial decreased their price target on Perspective Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. Lifesci Capital upgraded Perspective Therapeutics to a "strong-buy" rating in a research note on Saturday, July 12th. B. Riley restated a "buy" rating and issued a $12.00 price target (up from $9.00) on shares of Perspective Therapeutics in a research note on Monday, June 23rd. Finally, Wedbush restated an "outperform" rating and issued a $11.00 price target on shares of Perspective Therapeutics in a research note on Monday, June 23rd. One analyst has rated the stock with a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Perspective Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $12.56.
Check Out Our Latest Research Report on Perspective Therapeutics
About Perspective Therapeutics
(
Free Report)
Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.
Featured Articles
Before you consider Perspective Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Perspective Therapeutics wasn't on the list.
While Perspective Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access